{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000238","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.363318+00:00","generated_at":"2026-06-06T02:00:36.935519+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Q4 2023 revenue down 7.9% to $1.01B; non-GAAP EPS $2.46; 2024 guidance organic growth 0-3%","bullets":["Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.","Full-year 2023 revenue $4.13B (+3.9%); GAAP EPS $9.22; non-GAAP EPS $10.67.","2024 guidance: organic revenue growth 0%-3%; GAAP EPS $7.90-$8.40; non-GAAP EPS $10.90-$11.40.","Noveprim acquisition completed Nov 2023 (additional 41% stake for $144.6M, now 90% controlling interest).","DSA segment revenue fell 9.5% in Q4; Manufacturing organic growth +2.3% but revenue down 9.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000238","json":"https://secwatch.observer/filing/0001157523-24-000238.json","markdown":"https://secwatch.observer/filing/0001157523-24-000238.md","text":"https://secwatch.observer/filing/0001157523-24-000238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/a53896037.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:00:36.935519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08d2cd945e2dcfa18b95a43c6720deca46ca5395","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fourth quarter ended December 30, 2023 results: revenue $1.01 billion, net income $187.1 million, EPS $3.62 per share.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 30, 2023"},{"label":"Revenue","value":"$1.01 billion"},{"label":"Net income","value":"$187.1 million"},{"label":"EPS","value":"$3.62 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"13debe3cbb4a6f11bb686474e4a4cf70d769c89c","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. updated its 2024 guidance (initiated).","evidence_excerpt":"Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c22d4135a1dbc8e0fcbdfaeff2e7195c84c6dfce","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fiscal year ended December 30, 2023 results: revenue $4.13 billion, EPS $9.22 per share.","evidence_excerpt":"Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 30, 2023"},{"label":"Revenue","value":"$4.13 billion"},{"label":"EPS","value":"$9.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}